Vote Scores

Home / Companies / Reviva Pharmaceuticals Holdings, Inc. / 18 Dec 2025

Meeting · year to 30 June 202631 filers reporting

Reviva Pharmaceuticals Holdings, Inc.: meeting of 18 Dec 2025

Votes reported on Form N-PX, item by item

31 Form N-PX filers reported votes at the Reviva Pharmaceuticals Holdings, Inc. meeting of 18 Dec 2025. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

5 nominees; 100.0% of reported votes for; no filer withheld from or voted against at least one nominee.

35 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management3 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

41 vote records from 31 filers. 13 of the 27 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

41.9% for45.2% against12.9% other48.1% against management31 filers92.9% for7.1% against6.0% against management1,182,796 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

7 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management3 filers100.0% for0.0% against0.0% against management459,530 reported shares
4

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

14 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management3 filers100.0% for0.0% against0.0% against management919,060 reported shares, counted once per item in this group
5

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

7 vote records from 3 filers. 1 of the 3 filers that marked the item either way voted against management.

66.7% for33.3% against33.3% against management3 filers100.0% for0.0% against0.0% against management459,530 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesNo reportForNo report
FidelityForForFor
State Street and SPDRNo reportForNo report
Charles SchwabNo reportAgainst *No report
John Hancock and ManulifeForAgainst *For
Northern Trust and FlexSharesNo reportForNo report
BNY MellonNo reportAgainst *No report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Reviva Pharmaceuticals Holdings, Inc. meeting?

31 Form N-PX filers reported votes at the meeting of 18 Dec 2025. On say-on-pay, 13 of 27 voted against management (48.1%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Reviva Pharmaceuticals Holdings, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Reviva Pharmaceuticals Holdings, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Reviva Pharmaceuticals Holdings, Inc. with a meeting date within three days of 18 Dec 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.